Medtronic Endovascular
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Medtronic Endovascular sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Medtronic Endovascular: 25 sponsored US clinical trials, 2 recruiting.
Medtronic Endovascular sponsors 25 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 18 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Great Saphenous Vein (GSV) With Venous Reflux Disease, with 2 trials.
Top-decile sponsor footprint
Medtronic Endovascular ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
NCT07335341
Onyx™ Liquid Embolic IDE Clinical Study
NCT06742801
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
NCT04484220
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
NCT03820947
FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia
NCT04120610
CAPERE Thrombectomy System Post-Market Clinical Follow Up Study
NCT03869645
ABRE Clinical Study of the Abre Venous Self-expanding Stent System
NCT03038438
IN.PACT™ AV Access IDE Study
NCT03041467
VeClose Five Year Follow-Up Extension Study
NCT03455699
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
NCT02363972
VenaSeal Sapheon Closure System Pivotal Study (VeClose)
NCT01807585
EverFlex Post Approval Study
NCT01680835
IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)
NCT01566461
DURABILITY™ Iliac Study
NCT01400919
VISIBILITY™ Iliac Study
NCT01402700
Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study
NCT01341483
RFS (Radiofrequency Stylet) - Radiofrequency Perforator Vein Treatment Study
NCT01079598
Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)
NCT00880230
The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions
NCT00814970
The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
NCT00753337
The Complete® Self-Expanding Stent and Stent Delivery System Registry
NCT00730730
Proximal Protection With The Mo.Ma Device During Carotid Stenting
NCT00744523
Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
NCT00530504
ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
NCT00509392
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
NCT00619775
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
Where Medtronic Endovascular enrollment is open (later-stage tilt)
2 recruiting of 25 indexed (8% open); 18 completed (72%).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Great Saphenous Vein (GSV) With Venous Reflux Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Medtronic Endovascular: open-pipeline peers nationwide
Peers matched on 25 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Medtronic Endovascular sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Novartis Pharmaceuticals · 8% recruiting · 1,375 trials
- Penumbra · 8% recruiting · 25 trials
- SK Life Science · 8% recruiting · 25 trials
- Syndax Pharmaceuticals · 8% recruiting · 25 trials
Related
What to do with this Medtronic Endovascular page
25 registered trials is a research-attention snapshot, not an endorsement of Medtronic Endovascular or any single study.
- 2 of Medtronic Endovascular's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Great Saphenous Vein (GSV) With Venous Reflux Disease is the condition Medtronic Endovascular studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Great Saphenous Vein (GSV) With Venous Reflux Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medtronic Endovascular pipeline card: 25 registered trials from official public datasets.Report a data error.